First Global is out with its report today on Walgreens WAG, reiterating Market Perform.
In a note to clients, First Global writes, "WAG has decided not to renew its contract with pharmacy benefit
manager, Express Scripts Inc. ESRX, with effect from January 1, 2012, due to unfavorable terms put forth by the company, which are detrimental to its interests, as a result of which, is sales will be impacted
in the medium term. On the valuation front, the stock trades at a P/E of 15.8x and EV/EBIDTA of 7.7x our FY11 diluted EPS estimate. We reiterate our rating of Market Perform on Walgreen."
Shares of WAG closed Friday at $41.39, down 2.82% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted In:
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in